Follistatin 344 vs Sermorelin

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Follistatin-344 is the predominant endogenous isoform of follistatin, a glycoprotein that binds and neutralizes the TGF-β superfamily members activin A and myostatin, preventing their engagement with skeletal muscle ActRII receptors and thereby relieving their inhibitory effects on muscle protein synthesis and satellite cell activation. By sequestering both myostatin and activin A simultaneously, follistatin-344 neutralizes two complementary negative regulators of muscle growth through a dual-pathway mechanism, a property that distinguishes it from agents that target only the myostatin pathway. Transgenic expression of human follistatin-344 has produced significant skeletal muscle mass increases in animal models, and a phase 1/2a gene therapy trial delivering the follistatin-344 gene via AAV to patients with Becker muscular dystrophy established initial proof of concept and safety data in a human clinical context. Follistatin-344 has not received FDA approval for any indication; exogenous administration as a recombinant protein or peptide is investigational and no human safety data exists for this route of administration outside gene therapy trial contexts. Follistatin-344 as a research compound: recombinant follistatin-344 protein is available through research biochemical suppliers as a laboratory reagent, used in cell culture and animal models to probe myostatin and activin A biology. Interest in exogenous follistatin-344 administration in performance contexts has grown from the animal model hypertrophy data; however, the protein's large molecular weight (~35 kDa glycoprotein) creates significant bioavailability challenges for subcutaneous or intramuscular routes, and no human pharmacokinetic data supports assumed tissue distribution from injection. This distinguishes it from smaller peptide-based myostatin modulators. Follistatin-344 vs myostatin propeptide: both target myostatin inhibition but through different binding mechanisms. Follistatin-344 binds activin A in addition to myostatin, providing a broader TGF-β inhibition profile. Myostatin propeptide is the endogenous inhibitory domain of the myostatin precursor protein — it is myostatin-specific but structurally derived from the same protein rather than from a binding antagonist class. Both compounds remain at the research stage for performance applications with no approved human use. Providers offering research peptides in the performance and muscle recovery category are listed in the PeptideBase directory.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Sermorelin acetate is a synthetic 29-amino-acid peptide (GHRH(1-29)NH2) corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone, developed as a prescription pharmaceutical to stimulate endogenous GH secretion from the pituitary gland as a diagnostic and therapeutic agent for GH deficiency. Sermorelin acts on pituitary somatotrophs via GHRH receptors to stimulate pulsatile GH release, preserving the natural feedback regulation of the GH axis — an advantage over direct exogenous GH administration — and multiple randomized controlled trials have established its pharmacokinetic and pharmacodynamic profile in populations with GH insufficiency including post-irradiation hypopituitarism. The compound received FDA approval as Geref (Serono) for diagnosis and treatment of GH deficiency in children; approval was voluntarily withdrawn by the manufacturer in 2008 for commercial rather than safety reasons, leaving the underlying human evidence base intact, and compounded sermorelin has since been widely used off-label in adult anti-aging and hormone optimization practice. Sermorelin is currently available only through compounding pharmacies under prescriber supervision; it is not FDA-approved for any current indication, and its use in adults represents off-label prescribing outside the regulatory framework established by its original pediatric approval. Sermorelin is available through telehealth platforms and hormone optimization clinics across the United States and is dispensed by compounding pharmacies under licensed prescriber supervision. Patients searching for sermorelin providers near them or via telehealth can use the PeptideBase directory to browse verified clinics and telehealth platforms offering sermorelin by location. Sermorelin bodybuilding and anti-aging research contexts have driven its widespread compounded use in adults, though these applications are off-label and outside the original pediatric approval framework. Sermorelin near me: sermorelin is available through licensed anti-aging clinics, hormone health practices, and telehealth platforms that specialize in growth hormone axis support. Because sermorelin requires a prescription, access involves a clinical consultation — many providers now offer this remotely via telehealth, eliminating the need for in-person visits. For those searching for sermorelin providers near them, PeptideBase maintains a directory of verified clinics and telehealth platforms offering sermorelin protocols across the United States. Sermorelin and ipamorelin together: yes, sermorelin and ipamorelin are frequently combined in clinical research and compounded hormone optimization protocols. The two peptides act on different receptors — sermorelin on GHRH receptors (stimulating the GHRH pathway) and ipamorelin on ghrelin receptors (GHS-R1a) — and their mechanisms are complementary rather than redundant. Combining a GHRH analog like sermorelin with a GHRP like ipamorelin produces synergistic GH release, consistent with the well-established pharmacological principle that GHRH and GH secretagogues act additively at the pituitary. Ipamorelin is specifically valued in this combination for its selectivity — it stimulates GH without the cortisol or prolactin co-stimulation that characterizes less selective GHRPs such as GHRP-2 or GHRP-6. The sermorelin + ipamorelin combination (and its extension, the sermorelin + CJC-1295 + ipamorelin triple protocol) is among the most commonly prescribed compounded GH secretagogue regimens in anti-aging and hormone optimization practice. Providers offering combination GH secretagogue protocols are listed in the PeptideBase directory.